GLP-1受体激动剂与活动性癌症患者死亡及住院风险降低相关
该研究利用TriNetX全球数据库,比较接受GLP-1RA与二甲双胍治疗的2型糖尿病合并活动性癌症患者。结果显示GLP-1RA组全因死亡风险显著降低(总体HR 0.875;新起始HR 0.786),且住院、脓毒症、主要不良心血管事件等发生率更低。
要点
- 2型糖尿病合并活动性癌症患者使用GLP-1RA较二甲双胍全因死亡风险降低。
- GLP-1RA组全因住院、脓毒症、主要不良心血管事件、肺栓塞和肺炎发生率更低。
- 按BMI和HbA1c分层的亚组分析未达统计学显著性。
核心结论
- 合并糖尿病的活动性癌症患者接受GLP-1RA治疗较二甲双胍治疗具有更优的生存结局和更低的住院率。
- 已使用二甲双胍并新起始GLP-1RA的患者较新起始胰岛素的患者生存结局更优。
研究设计与样本
- 亚组分析按HbA1c范围、肥胖及新起始GLP-1RA(癌症治疗3个月内首次使用)分层。
主要发现
- 次要分析显示GLP-1RA组全因住院、脓毒症、主要不良心血管事件、肺栓塞和肺炎发生率更低。
- 按BMI和HbA1c分层的亚组分析未达统计学显著性。
临床怎么用
- 对于2型糖尿病合并活动性癌症的患者,GLP-1RA可作为降糖治疗选择之一,可能带来生存和住院获益。
- 临床决策需结合患者具体情况,并关注尚需前瞻性研究验证的局限性。
局限性
- 回顾性研究设计存在残余混杂可能。
- 按BMI和HbA1c分层的亚组分析未达统计学显著性。
- 需要进一步前瞻性、良好对照的研究评估GLP-1RA在糖尿病合并癌症患者中的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1RAs inhibit progression of solid tumor malignancies via downregulation of cellular proliferation pathways and improved glycemic control. Despite these promising findings, studies characterizing the effects of GLP-1RAs in patients with active cancer are limited. OBJECTIVE: To evaluate the effects of GLP-1RAs on mortality and hospitalization in patients with type 2 diabetes and active cancer compared to those receiving metformin. METHODS: Using TriNetX, a global database comprising more than 120 million patients, we identified an overall cohort of 3747 patients with type 2 diabetes who received GLP-1RAs within 3 months of starting systemic therapy and identified 52 061 patients receiving metformin in the same timeframe as a control cohort. Additional subanalyses stratified patients by glycated hemoglobin A1c (HbA1c) range, obesity, and by participants "newly started" on their first instance of GLP-1 RA within 3 months of starting cancer treatment. RESULTS: Patients receiving GLP-1RAs had significantly reduced mortality both in the overall monotherapy setting (hazard ratio [HR]: 0.875; 95% CI, 0.778-0.985; P = .0268) and the new-start setting (HR: 0.786; 95% CI, 0.662-0.934; P = .0062) cohorts. Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism, and pneumonia in patients on GLP-1RAs. Subanalyses stratified by body mass index and HbA1c did not meet statistical significance. CONCLUSION: Patients with diabetes and cancer who received GLP-1RAs experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin. Additionally, patients already on metformin and newly started on GLP-1RAs demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the benefits of GLP-1RAs in patients with diabetes and cancer.
引用
- Mahadevan A, Vosooghi A, Arora JS, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. J Clin Endocrinol Metab. 2026. PMID: 41482652. doi:10.1210/clinem/dgaf703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。